AQSZF AEQUUS PHARMACEUTICALS

Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference

Aequus to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference

VANCOUVER, British Columbia, April 19, 2021 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX: AQS, OTCQB: AQSZF), a Canadian based specialty pharmaceutical company, will be presenting at the 2021 Bloom Burton & Co. Healthcare Investor Conference. Chairman and CEO, Doug Janzen, is scheduled to present at the conference on:

Wednesday, April 21st, 2021 at 8:30 A.M. PT (11:30 AM ET).

This conference and presentation shall be held virtually. To register, please visit the registration page at the following link:

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Bloom Burton & Co.

Bloom Burton & Co. (Bloom Burton Securities Inc.) is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, business strategy and scientific consulting, advisory on direct investing and company creation and incubation services. Bloom Burton Securities Inc. is a member of the Investment Industry Regulatory Organization of Canada (IIROC) and is also a member of the Canadian Investor Protection Fund (CIPF).

Aequus Contact Information:

Aequus Investor Relations

Email:

Phone: 604-336-7906



EN
19/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AEQUUS PHARMACEUTICALS

 PRESS RELEASE

Aequus Reports Second Quarter 2023 Financial Highlights and General Up...

Aequus Reports Second Quarter 2023 Financial Highlights and General Update VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended June 30, 2023 (“Second Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Doug Janzen shares that “we are very optimistic with the launch ...

 PRESS RELEASE

Aequus Announces Zimed PF Now Available in Canada

Aequus Announces Zimed PF Now Available in Canada VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: , OTCQB: ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. "This marks a new growth phase for Aequus and the launch of a Preservative Free (PF) innovation that brings value to both physicians and patients in a large therapeutic eye category,” says Grant Larsen, Chief Comm...

 PRESS RELEASE

Aequus Announces Zimed PF Website Launch

Aequus Announces Zimed PF Website Launch VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: , OTCQB: ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals. With a focus on elevated, interocular pressure, Glaucoma and Dry Eye Disease, this website features Zimed® PF, the first preservative-free multi-dose Bimatoprost available in Canada. The response from Canadian physicians at the 2023 annual COS conference in Quebec City...

 PRESS RELEASE

Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Inte...

Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: , OTCQB: ), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications. Un...

 PRESS RELEASE

Aequus Announces Financing to Support Launch of Zimed Preservative Fre...

Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$400,000 (the “Loan”). The Loan bears interest at an annual rate of two and a half percent (2.5%) to be calculated ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch